Imbruvica® (ibrutinib) – Indication withdrawals
April 6, 2023 - Janssen and AbbVie announced that they intend to voluntarily withdraw the indications for Imbruvica (ibrutinib) for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy and adult patients with marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy.
Top